Market Overview

Top 4 NASDAQ Stocks In The Drugs-Generic Industry With The Highest ROE

Share:
Related AKRX
Piper Jaffray: Akorn's Stock Will Be Delisted In 2016
Piper Jaffray Makes 15 'Provocative' Predictions For Biopharma Sector In 2016
Related SLXP
Benzinga's Volume Movers
US Stock Futures Edge Lower Ahead Of ADP Report

Below are the top drugs-generic stocks on the NASDAQ in terms of return on equity.

The trailing-twelve-month return on equity at Akorn (NASDAQ: AKRX) is 18.99%. Akorn's revenue for the same period is $227.26 million.

The trailing-twelve-month return on equity at Hi Tech Pharmacal Co (NASDAQ: HITK) is 18.38%. Hi Tech Pharmacal's operating margin for the same period is 24.58%.

The trailing-twelve-month return on equity at Salix Pharmaceuticals (NASDAQ: SLXP) is 15.84%. Salix Pharmaceuticals had $775.90 million in total cash for the latest quarter.

The trailing-twelve-month return on equity at Mylan (NASDAQ: MYL) is 14.65%. Mylan's PEG ratio is 0.72.

Posted-In: Drugs-Generic Industry highest ROE NASDAQTrading Ideas

 

Related Articles (AKRX + HITK)

Get Benzinga's Newsletters